VEGF Inhibitor Implant Preserves Visual Acuity, Retinal Anatomy in Wet AMD
DENVER — A sustained-release VEGF inhibitor implant outperformed standard anti-VEGF therapy for maintaining visual acuity in neovascular, or wet, age-related macular degeneration (AMD), showed a randomized trial reported here. Among patients with good baseline visual acuity, 74.1% maintained that status at 36 weeks with the axitinib implant OTX-TKI as compared with 55.8% taking standard-dose aflibercept…
